Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 13

1.

Critical appraisal of rituximab in the maintenance treatment of advanced follicular lymphoma.

Aguiar-Bujanda D, Blanco-Sánchez MJ, Hernández-Sosa M, Galván-Ruíz S, Hernández-Sarmiento S.

Cancer Manag Res. 2015 Oct 27;7:319-30. doi: 10.2147/CMAR.S69145. eCollection 2015. Review.

2.

Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma.

Mir MA, Maurer MJ, Ziesmer SC, Slager SL, Habermann T, Macon WR, Link BK, Syrbu S, Witzig T, Friedberg JW, Press O, LeBlanc M, Cerhan JR, Novak A, Ansell SM.

Blood. 2015 Feb 5;125(6):992-8. doi: 10.1182/blood-2014-06-583369. Epub 2014 Nov 24.

3.

Human interferon alpha-2b: a therapeutic protein for cancer treatment.

Asmana Ningrum R.

Scientifica (Cairo). 2014;2014:970315. doi: 10.1155/2014/970315. Epub 2014 Mar 10. Review.

4.

Anti-CD20-interferon-β fusion protein therapy of murine B-cell lymphomas.

Trinh KR, Vasuthasawat A, Steward KK, Yamada RE, Timmerman JM, Morrison SL.

J Immunother. 2013 Jun;36(5):305-18. doi: 10.1097/CJI.0b013e3182993eb9.

5.

Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma.

Bachy E, Houot R, Morschhauser F, Sonet A, Brice P, Belhadj K, Cartron G, Audhuy B, Fermé C, Feugier P, Sebban C, Delwail V, Maisonneuve H, Le Gouill S, Lefort S, Brousse N, Foussard C, Salles G; Groupe d'Etude des Lymphomes de l'Adulte (GELA).

Haematologica. 2013 Jul;98(7):1107-14. doi: 10.3324/haematol.2012.082412. Epub 2013 May 3.

6.

Follicular lymphoma - treatment and prognostic factors.

Luminari S, Bellei M, Biasoli I, Federico M.

Rev Bras Hematol Hemoter. 2012;34(1):54-9. doi: 10.5581/1516-8484.20120015.

7.

Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer.

Haabeth OA, Lorvik KB, Hammarström C, Donaldson IM, Haraldsen G, Bogen B, Corthay A.

Nat Commun. 2011;2:240. doi: 10.1038/ncomms1239.

9.

Treatment of follicular non-Hodgkin's lymphoma with or without rituximab: cost-effectiveness and value of information based on a 5-year follow-up.

Soini EJ, Martikainen JA, Nousiainen T.

Ann Oncol. 2011 May;22(5):1189-97. doi: 10.1093/annonc/mdq582. Epub 2010 Dec 6.

10.

Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma.

Xuan C, Steward KK, Timmerman JM, Morrison SL.

Blood. 2010 Apr 8;115(14):2864-71. doi: 10.1182/blood-2009-10-250555. Epub 2010 Feb 4.

11.

AAV-mediated local delivery of interferon-beta for the treatment of retinoblastoma in preclinical models.

Shih CS, Laurie N, Holzmacher J, Spence Y, Nathwani AC, Davidoff AM, Dyer MA.

Neuromolecular Med. 2009;11(1):43-52. doi: 10.1007/s12017-009-8059-0. Epub 2009 Mar 22.

12.

Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study.

Hochster H, Weller E, Gascoyne RD, Habermann TM, Gordon LI, Ryan T, Zhang L, Colocci N, Frankel S, Horning SJ.

J Clin Oncol. 2009 Apr 1;27(10):1607-14. doi: 10.1200/JCO.2008.17.1561. Epub 2009 Mar 2.

13.

Monocyte derived dendritic cells generated by IFN-alpha acquire mature dendritic and natural killer cell properties as shown by gene expression analysis.

Korthals M, Safaian N, Kronenwett R, Maihöfer D, Schott M, Papewalis C, Diaz Blanco E, Winter M, Czibere A, Haas R, Kobbe G, Fenk R.

J Transl Med. 2007 Sep 25;5:46.

Supplemental Content

Support Center